Report of Foreign Issuer (6-k)
October 26 2016 - 4:13PM
Edgar (US Regulatory)
United
States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Month of October, 2016
Commission File Number: 001-35892
GW
PHARMACEUTICALS PLC
(Translation of registrant’s name
into English)
Sovereign
House
Vision
Park
Histon
Cambridge
CB24 9BZ
United
Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Other Events
On October 26, 2016, GW Pharmaceuticals plc (the “Company”),
issued a regulatory news service (“RNS”) announcement setting forth details of a gift of 250,000 ordinary shares par
value £0.001per share (“Ordinary Shares”) by Dr Geoffrey Guy, the Company’s Chairman and member of its
board of directors to a family member. This RNS is attached as Exhibit 99.1 hereto and is incorporated by reference herein. On
October 25, 2016, the Company issued an RNS with details of transactions by its Directors in the Company’s Ordinary Shares
and American Depositary Shares. This RNS is attached as Exhibit 99.2 hereto and is incorporated by reference herein. The information
contained in Exhibit 99.1 and Exhibit 99.2 hereto shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing.
99.1
|
|
Regulatory news service announcement dated October 26, 2016
|
99.2
|
|
Regulatory news service announcement dated October 25, 2016
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
GW Pharmaceuticals plc
|
|
|
|
By:
|
/s/ Adam George
|
|
Name:
|
Adam George
|
|
Title:
|
Chief Financial Officer
|
|
|
|
Date: October 26, 2016
|
|
|